Anavex Life Sciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 40
- Market Cap
- $515.5M
- Website
- http://www.anavex.com
- Introduction
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Blarcamesine Shows Significant Slowing of Alzheimer's Disease Progression
Blarcamesine, a novel treatment for early-stage Alzheimer's disease, showed safety and significant slowing of clinical decline in a phase 2b/3 study. It demonstrated meaningful effects on biomarkers and reduced brain atrophy, with plans for a European regulatory submission in Q4 2024. Adverse events were mild and manageable.
Results from Anavex Life Sciences Landmark Phase IIb/III Study on Blarcamesine for Early Alzheimer's Treatment
Blarcamesine, an oral treatment for early Alzheimer's, significantly slowed clinical decline by 38.5% and 34.6% at 50 mg and 30 mg doses, respectively, over 48 weeks. It showed benefits on amyloid-beta and brain volume, with a good safety profile and no neuroimaging adverse events. EMA submission expected Q4 2024.
Anavex's Phase 2b/3 Trial of Blarcamesine Shows Significant Slowing of Cognitive Decline in Early Alzheimer's Disease
Anavex Life Sciences Corp. announced that blarcamesine (ANAVEX®2-73) significantly slowed cognitive decline in early Alzheimer's disease, with reductions in amyloid beta levels and brain atrophy. The Phase 2b/3 trial involved 508 participants across 52 centers, showing promising results with a good safety profile.
© Copyright 2025. All Rights Reserved by MedPath